![Antony Mattessich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 175 545 $ in data 31/05/2026
Antony Mattessich is currently an Independent Non-Executive Director at Aura Biosciences, Inc. since 2021.
Former roles include Chief Executive Officer & Director at Amphista Therapeutics Ltd. from 2024 to 2026, President, Chief Executive Officer & Director at Ocular Therapeutix, Inc. from 2017 to 2024, President, Chief Executive Officer & Director at Mundipharma International Ltd. in 2017, Managing Director & Director at Napp Pharmaceutical Holdings Ltd. from 2005 to 2011, Head-Therapeutic Franchise at Novartis AG from 2003 to 2005, and Head of Operations-International Medicines at Bristol Myers Squibb Co. Education includes graduate studies at The Trustees of Columbia University in The City of New York and undergraduate studies at the University of California, Berkeley.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
AURA BIOSCIENCES INC 0,04% | 17/06/2025 | 23.500 ( 0,04% ) | 175 545 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 29/09/2021 |
| Società | Posizione | Fine |
|---|---|---|
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Develops biotechnology products | Amministratore Delegato | 18/03/2026 |
| OCULAR THERAPEUTIX, INC. | Amministratore Delegato | 15/04/2024 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Amministratore Delegato | 18/12/2017 |
Napp Pharmaceutical Holdings Ltd.
 Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops and provides medicines to patients | Amministratore Delegato | 01/05/2011 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2005 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Ocular Therapeutix, Inc.
 Ocular Therapeutix, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for retinal diseases & conditions of the eye | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Napp Pharmaceutical Holdings Ltd.
Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops and provides medicines to patients | Health Technology |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
